Central veins in brain lesions visualized with high-field magnetic resonance imaging: a pathologically specific diagnostic biomarker for inflammatory demyelination in the brain.

IMPORTANCE There is no single test that is diagnostic for multiple sclerosis (MS), and existing diagnostic criteria are imperfect. This can lead to diagnostic delay. Some patients require multiple (sometimes invasive) investigations, and extensive clinical follow-up to confirm or exclude a diagnosis of MS. A diagnostic biomarker that is pathologically specific for the inflammatory demyelination in MS could overhaul current diagnostic algorithms. OBJECTIVE To prospectively assess the diagnostic value of visualizing central veins in brain lesions with magnetic resonance imaging (MRI) for patients with possible MS for whom the diagnosis is uncertain. DESIGN Prospective longitudinal cohort study. The reference standard is a clinical diagnosis that is arrived at (after a mean follow-up of 26 months) by the treating neurologist with a specialist interest in MS. The 7-T MRI scans were analyzed at baseline, by physicians blinded to the clinical data, for the presence of visible central veins. SETTING Academic MS referral center. PARTICIPANTS A consecutive sample of 29 patients referred with possible MS who had brain lesions detected on clinical MRI scans but whose condition remained undiagnosed despite expert clinical and radiological assessments. EXPOSURE Seven-Tesla MRI using a T2*-weighted sequence. MAIN OUTCOMES AND MEASURES The proportion of patients whose condition was correctly diagnosed as MS or as not MS, using 7-T MRI at study onset, compared with the eventual diagnosis reached by treating physicians blinded to the result of the MRI scan. RESULTS Of the 29 patients enrolled and scanned using 7-T MRI, so far 22 have received a clinical diagnosis. All 13 patients whose condition was eventually diagnosed as MS had central veins visible in the majority of brain lesions at baseline. All 9 patients whose condition was eventually not diagnosed as MS had central veins visible in a minority of lesions. CONCLUSIONS AND RELEVANCE In our study, T2*-weighted 7-T MRI had 100% positive and negative predictive value for the diagnosis of MS. Clinical application of this technique could improve existing diagnostic algorithms.

[1]  P S Morgan,et al.  Ultra-high-field imaging distinguishes MS lesions from asymptomatic white matter lesions , 2011, Neurology.

[2]  Helen Tremlett,et al.  Factors associated with delay to medical recognition in two Canadian multiple sclerosis cohorts , 2010, Journal of the Neurological Sciences.

[3]  Ludwig Kappos,et al.  Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study , 2007, The Lancet.

[4]  T. Ben-Hur,et al.  Patterns of misdiagnosis of multiple sclerosis. , 2003, The Israel Medical Association journal : IMAJ.

[5]  Seth Love,et al.  Greenfield's neuropathology , 2015 .

[6]  J. Stockman,et al.  Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study , 2009 .

[7]  A. Rovira,et al.  Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? , 2008, Neurology.

[8]  F. Barkhof,et al.  The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis , 1999, Neurology.

[9]  Peter Gordon Morris,et al.  Optimisation of T₂*-weighted MRI for the detection of small veins in multiple sclerosis at 3 T and 7 T. , 2013, European journal of radiology.

[10]  Marco Rovaris,et al.  Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study , 2001, The Lancet.

[11]  T. Fog ON THE VESSEL‐PLAQUE RELATIONSHIPS IN THE BRAIN IN MULTIPLE SCLEROSIS , 1964, Acta neurologica Scandinavica. Supplementum.

[12]  D Miller,et al.  The differential diagnosis of multiple sclerosis , 2006, McAlpine's Multiple Sclerosis.

[13]  J H Simon,et al.  Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. , 2000, The New England journal of medicine.

[14]  P. Pretorius,et al.  The role of MRI in the diagnosis of MS. , 2003, Clinical radiology.

[15]  F Barkhof,et al.  MR venography of multiple sclerosis. , 2000, AJNR. American journal of neuroradiology.

[16]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[17]  J. Benito-León,et al.  Accuracy of MRI criteria for dissemination in space for the diagnosis of multiple sclerosis in patients with clinically isolated syndromes , 2010, Multiple sclerosis.

[18]  Jullie W Pan,et al.  DEMONSTRATING THE PERIVASCULAR DISTRIBUTION OF MS LESIONS IN VIVO WITH 7-TESLA MRI , 2008, Neurology.